Health

The heath and nutrition product manufacturer's Otsuka Nutraceutical Emerging Ventures vehicle will target early-stage investments in North America.

AGC, JSR Life Sciences and Merck & Co all scored exits as the synthetic biology technology developer floated on Nasdaq, whose valuation reportedly stands at nearly $2bn.

Takeda has returned to back the cancer therapeutics developer’s series D round after committing $120m in equity and milestone financing just over 18 months ago.

Our data suggest that valuations in the HR tech space are picking up. Two deals stories from last week confirm the trend.

Branding services provider Tailor Brands raised $50m in a GoDaddy-led series C round while Orix is set to exit hiring software developer PandoLogic in a $150m acquisition.

UC Berkeley’s cancer therapy developer priced a $304m initial public offering at the top of its range.

Yale University is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.

The Corteva, Novartis, AbbVie and Heritage Medical Systems-backed cancer therapy developer priced a $304m initial public offering at the top of its range.

Baidu Ventures and AliHealth both invested in a series C round for the genome sequencing technology provider, which counts BGI as an existing investor.

Unilever Ventures and Sistema Asia Capital have backed the health and fitness app developer’s latest round, which took its overall funding past $100m.

Several corporates backed a $68m series D round for microbiome drug developer Vedanta Biosciences while grooming brand owner Pangaea raised the same amount from investors including Unilever.